Skip to main content
. Author manuscript; available in PMC: 2018 Nov 28.
Published in final edited form as: J Control Release. 2017 Oct 5;266:248–255. doi: 10.1016/j.jconrel.2017.09.043

Figure 1.

Figure 1

Radiation-enhanced delivery of amph-CpG increases anti-tumor effectiveness. A) CpG ODN conjugated to a 5′ diacyl lipid tail and a 3′ ROX dye to create fluorescent amph-CpG. B) Targeted radiotherapy increases the tumor accumulation of systemically administered amph-CpG, as observed through IVIS fluorescence imaging (black to yellow gradient). C) IVIS quantification of tumor fluorescence measured at multiple time points shows significantly increased accumulation and retention of amph-CpG in irradiated tumors. n = 3–5 for each data set; * p ≤ 0.05. D) Tumor growth significantly decreases over time following IR + amph-CpG treatment. Red denotes time points where combination treatment significantly decreased tumor size relative to IR alone. n = 5–9 for each data set; p ≤ 0.05.